This research article is focused on the mapping of lymphatic filariasis (LF) in Loa loa endemic health districts in forest areas of Cameroon.
Beng et al., 2020 (1.68 MB)
This research article focuses on the results of four rounds of mass drug administration (MDA) for cross-border districts of Côte d’Ivoire where lymphatic filariasis (LF) is endemic.
Yokoly et al., 2020 (1.05 MB)
In order to confirm that transmission recrudescence or importation does not occur for lymphatic filariasis (LF) after mass drug administration (MDA), the WHO recommends post-treatment surveillance.
Eigege et al., 2020 (321.96 KB)
This research article examines the Ov16 (onchocerciasis) and Wb123 (lymphatic filariasis) seroprevalence in the Bakoye and Falémé foci in Mali after 24 – 25 years of treatment.
Dolo et al., 2020 (1.05 MB)
This editorial from Darin S. Evans raises important questions regarding the decision to stop mass drug administration (MDA) for countries with onchocerciasis as they approach transmission interruption.
Evans, 2020 (38.33 KB)
This research paper focuses on the first stop-Mass Drug Administration (MDA) decision for onchocerciasis in Nigeria. These findings can be modeled by other African countries to advance their MDA programs to reach similar levels of success.
Richards et al., 2020 (803.37 KB)
This research paper details the coordinated stop of MDA, decided by Sudan and Ethiopia, due to satisfying the World Health Organization’s criteria for interruption of onchocerciasis transmission.
Katabarwa et al., 2020 (3.04 MB)
on the importance of cross-border issues in onchocerciasis elimination programmes. Bush, Sodahlon, Downs and Mackenzie, International Health, Volume 10, Issue suppl_1, 1 March 2018, Pages i54–i59.
Article on the use of alternative (or complementary) treatment strategies (ATSs) to accelerate the elimination of onchocerciasis. Boussinesq et al., International Health, Volume 10, Issue suppl_1, 1 March 2018, Pages i40–i48.
Article on eliminating onchocercias as a public health problem in Uganda. Katabarwa et al, International Health, Volume 10, Issue suppl_1, 1 March 2018, Pages i79–i88.
A review summarizing the progress made in identifying diagnostics that meet the specialized requirements needed to verify onchocerciasis elimination, as well as a discussion of why these tests were selected and a summary of the needs that still exist to complete the arsenal of diagnostic tools that will be useful as the goal of elimination is achieved.
on the acquisition of quality-assured (QA) data that ultimately define the absence of infection or transmission of onchocerciasis in previously endemic areas in Africa.
This publication reviews the history of the efforts to control onchocerciasis in Yemen and the current status of the disease, and identifies the essential changes needed to a mass drug administration (MDA) approach as the national program addresses elimination.
Journal article discussing the concept that all areas where the worm that causes onchocerciasis might currently be transmitted—and where mass drug administration (MDA) with ivermectin treatment has not been delivered previously—must now be identified by careful, detailed “elimination mapping”.
The purpose of this publication is to provide proof of concept that, through a strong partnership between Merck’s donation of Mectizan, the endemic countries and donors, we can eliminate onchocerciasis, a scourge that was once classified as a disease that could only be controlled.
discussing reducing the cost of the test and not treat (TaNT) strategy with a smaller team (three people) selected within affected communities.
This article addresses elimination of onchocerciasis transmission in the Americas. With four of the six originally endemic American countries now WHO verified as having eliminated onchocerciasis transmission, and 95% of ivermectin treatments in the region halted, the regional focus is now on the remaining active transmission zone, called the Yanomami Area, on the border between Venezuela and Brazil.
regarding the status of onchocerciasis transmission in black flies as assessed in five countries in Africa. International Health, Volume 10, Issue suppl_1, 1 March 2018, Pages i27–i32.